Target-sensitive immunoliposomes- preparation and characterization
First Claim
1. Target sensitive immunoliposomes consisting essentially of phosphatidylethanolamine and a stabilizing amount of fatty acid (C12 to C24) derivatized antibody, said antibody having an affinity for the target cell surface which immunoliposomes release their entrapped contents upon binding to a target cell surface.
1 Assignment
0 Petitions
Accused Products
Abstract
Novel target-sensitive immunoliposomes were prepared and characterized. In this invention, target specific binding of antibody-coated liposomes was sufficient to induce bilayer destabilization, resulting in a site-specific release of liposome contents.
Unilamellar liposomes were prepared by using a small quantity of palmitoyl IgG (pIgG) to stabilize the bilayer phase of the unsaturated phosphatidylethanol amine (PE) which by itself does not form stable liposomes. A mouse monoclonal IgG antibody to the glycoprotein D (gD) of Herpes Simplex Virus (HSV) and dioleoyl PE were used in one preferred embodiment.
In another preferred embodiment, potentially cytotoxic antiviral drugs were entrapped in target sensitive (TS) immunoliposomes and delivered to HSV infected cells. Potency was as much as 1000 times superior to the free drug and cytotoxicity was decreased by as much as 3000 fold.
-
Citations
20 Claims
- 1. Target sensitive immunoliposomes consisting essentially of phosphatidylethanolamine and a stabilizing amount of fatty acid (C12 to C24) derivatized antibody, said antibody having an affinity for the target cell surface which immunoliposomes release their entrapped contents upon binding to a target cell surface.
-
15. A method of delivering therapeutic agents to the surface of cells in need of such treatment comprising the steps of:
-
(a) forming target sensitive immunoliposomes from phosphatidylethanolamine and a stabilizing amount of fatty acid (C12 to C24) derivatized antibody, said antibody having an affinity for the target cell surface; (b) entrapping one or more therapeutic agents within the immunoliposomes of step (a); and (c) administering the immunoliposomes prepared in step (b) to a patient in need of such treatment. - View Dependent Claims (16, 17, 18, 19, 20)
-
Specification